12 Small Cap Stocks to Buy with Huge Upside Potential

Page 5 of 11

7. Pharvaris N.V. (NASDAQ:PHVS)

Analyst Upside: 75.83%

Market Cap: $1.54 billion

Number of Hedge Fund Holders: 30

Pharvaris N.V. (NASDAQ:PHVS) is one of the best small cap stocks to buy with huge upside potential. Morgan Stanley analyst Maxwell Skor reiterated a Buy rating on Pharvaris N.V. (NASDAQ:PHVS) on December 15, setting a $41 price target. Pharvaris N.V. (NASDAQ:PHVS) also received a rating update from Oppenheimer on December 4, with the company reaffirming an Outperform rating on the stock and lifting the price target to $50 from $44.

The firm told investors that the company reported positive top-line results for the pivotal RAPIDe-3 study confirming potential of deucrictibant for on-demand treatment of HAE attacks. Pharvaris N.V. (NASDAQ:PHVS) reported the results on December 3, stating that the study met the primary endpoint, with the median time to onset of symptom relief attained in 1.28 hours, significantly faster versus placebo.

In addition, all secondary efficacy endpoints were met, including End of Progression (median 17.47 minutes) and complete symptom resolution (median 11.95 hours). The results confirmed the well-tolerated safety profile of deucrictibant, with efficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with normal C1 inhibitor) and varying attack severities and locations.

Pharvaris N.V. (NASDAQ:PHVS) further reported that data from the pivotal Phase 3 would be used as the basis for marketing authorization applications, which the company plans to start filing in H1 2026.

Pharvaris N.V. (NASDAQ:PHVS) is a clinical-stage company that develops and commercializes innovative therapies for rare diseases, with a focus on angioedema and other bradykinin-mediated diseases.

Page 5 of 11